06/08/2026
Report No. 6: Follow-up on the Use of Convupidiol® in Patients with Refractory (Drug-Resistant) Epilepsy
Pharmacovigilance reports
Download PDF here
01/08/2026
Effectiveness and Safety of Cannabidiol (100 mg Twice Daily) for Central Neuropathic Pain in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: Preliminary Findings from a Multicentre Pilot study.
Otros
Summary: Study on the use of Convupidiol in central neuropathic pain associated with multiple sclerosis and neuromyelitis optic...
14/04/2026
Real-world effectiveness and tolerability of highly purified cannabidiol in patients with monogenic developmental and epileptic encephalopathies with highly active epilepsy
Epilepsia
Download PDF here
10/07/2025
Report No. 5: Follow-up on the Use of Convupidiol® in Patients with Refractory (Drug-Resistant) Epilepsy
Pharmacovigilance reports
Download PDF here
07/07/2025
A Multicenter study on the use of purified cannabidiol for children with treatment – resistant developmental and epileptic encephalopathies (551 patient)
Epilepsia
Summary: Study analyzing the efficacy and safety of purified cannabidiol (Convupidiol®) as an add-on therapy in 551 ch...
16/02/2025
Purified cannabidiol leads to improvement of severe treatment-resistant behavioral symptoms in children with autism spectrum disorder
Otros
Summary: Prospective study evaluating the use of purified cannabidiol (CBD) as an add-on therapy in 20 children with sever...
05/01/2025
Expanding The Therapeutic role of highly purified cannabidiol in monogenic epilepsies : A multicenter real world study
Epilepsia
Summary: An international study evaluating the efficacy of purified cannabidiol (Epidiolex/Convupidiol) in 266 patients wi...
30/11/2024
Population pharmacokinetics of cannabidiol and the impact of food and formulation on systemic exposure in children with drug-resistant developmental and epileptic encephalopathies
Epilepsia
Summary: Describing the pharmacokinetic profile of cannabidiol in 48 children with treatment-resistant epileptic encephalo...
06/11/2024
Report No. 4: Follow-up on the Use of Convupidiol® in Patients with Refractory (Drug-Resistant) Epilepsy
Pharmacovigilance reports
Marketing Authorization Holder (MAH): ALEFCutoff date: September 30, 2024Download PDF here
11/05/2024
Purified cannabidiol as add-on therapy in children with treatment-resistant infantile epileptic spasms síndrome
Otros
Summary: Efficacy and safety of Convupidiol® in 28 infants with drug- and ketogenic diet–resistant infantile spa...
03/05/2023
Cannabidiol in children with treatment-resistant epilepsy with myoclonic-atonic seizures
Epilepsia
Summary: Multicenter study evaluating the efficacy and tolerability of CONVUPIDIOL in patients with epilepsy with myocloni...
04/05/2023
Real-World Evidence of Factors Affecting Cannabidiol Exposure in Children with Drug-Resistant Developmental and Epileptic Encephalopathies
Summary: Published in the journal Pharmaceutics.The study included 22 patients and was conducted by the team at Prof. Dr. Juan ...